

Zydus signs in-licensing deal with Neovii of Switzerland

07 October 2016 | News | By BioSpectrum Bureau

Zydus signs in-licensing deal with Neovii of Switzerland



The Ahmedabad headquartered, Zydus group has entered into an in-licensing agreement with Neovii, a Switzerland based global biopharmaceutical company to launch Grafalon ,an immunosuppressant extensively used in solid organ transplants and Stem Cell Transplant, in India. Neovii has been dedicated for over three decades to improve the outcomes in transplantation medicine, hemato-oncological and immune disorders.

The Zydus group will market this therapy through Zydus Trans-immune, a division that offers a range of therapies related to transplant medicine. With the inclusion of Grafalon, Zydus Trans-immune becomes a leading player in transplant-immuno therapy segment and will be able to offer the most comprehensive therapy portfolio in solid organ transplant and stem cell transplant.

The market for transplant-immuno therapies is estimated at Rs. 483 crore.(Source IPSOS) Organ transplantation is the most preferred option for patients with end-stage organ failure since both survival and quality of life are superior as compared to patients who live without transplantation. However, one of the major challenges in organ transplantation is graft rejection. In most cases, transplant rejection occurs when transplanted tissue is rejected by the recipient's immune system, which destroys the transplanted tissue. Likewise, Stem Cell Transplantation remains key treatment option for those suffering from haematological conditions including malignancies.

Transplant outcomes can be improved significantly by the use of immunosuppressant drugs like Grafalon. Grafalon (formerly commercialized as ATG Fresenius) is used as a part of immunosuppressive regimens (induction protocol) for the prevention and treatment of rejection in solid organ transplantation, prevention of graft versus host disease in stem cell transplantation.

As an rATG anti-human T-lymphocyte globulin, Grafalon enjoys worldwide recognition among solid organ and stem cell transplant teams and has transformed the way transplant teams manage the care of transplant recipients around the world.

